ICU Medical, Inc. (FRA:IC7)
Germany · Delayed Price · Currency is EUR 132.00
+6.00 (4.76%)
At close: Feb 20, 2026
ICU Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,231 | 2,382 | 2,259 | 2,280 | 1,316 |
Revenue | 2,231 | 2,382 | 2,259 | 2,280 | 1,316 |
Revenue Growth (YoY) | -6.33% | 5.44% | -0.92% | 73.21% | 3.56% |
Cost of Revenue | 1,409 | 1,557 | 1,519 | 1,582 | 824.82 |
Gross Profit | 822.04 | 824.78 | 739.87 | 697.76 | 491.49 |
Selling, General & Admin | 625.21 | 638.76 | 606.69 | 608.35 | 302.58 |
Research & Development | 87.5 | 88.62 | 85.34 | 92.98 | 47.5 |
Operating Expenses | 712.71 | 727.38 | 692.04 | 701.33 | 350.08 |
Operating Income | 109.33 | 97.41 | 47.84 | -3.57 | 141.41 |
Interest Expense | -93.34 | -106.54 | -102.73 | -70.81 | -0.86 |
Interest & Investment Income | 10.31 | 10.79 | 7.51 | 4.43 | 2.84 |
Earnings From Equity Investments | -1.19 | - | - | - | - |
Currency Exchange Gain (Loss) | 3.79 | -9.79 | -5.92 | -5.78 | -1.02 |
Other Non Operating Income (Expenses) | 0.35 | -1.82 | -2.43 | 3.2 | 0.63 |
EBT Excluding Unusual Items | 29.25 | -9.96 | -55.74 | -72.53 | 143 |
Merger & Restructuring Charges | -66.51 | -59.84 | -41.26 | -71.42 | -18.04 |
Gain (Loss) on Sale of Assets | 40.43 | -1.61 | -0.15 | -2.55 | -1.65 |
Other Unusual Items | - | 5.4 | 16.25 | 32.09 | -0.13 |
Pretax Income | 3.17 | -66.01 | -78.3 | -114.41 | 123.19 |
Income Tax Expense | 2.44 | 51.68 | -48.64 | -40.12 | 20.05 |
Net Income | 0.73 | -117.69 | -29.66 | -74.29 | 103.14 |
Net Income to Common | 0.73 | -117.69 | -29.66 | -74.29 | 103.14 |
Net Income Growth | - | - | - | - | 18.72% |
Shares Outstanding (Basic) | 25 | 24 | 24 | 24 | 21 |
Shares Outstanding (Diluted) | 25 | 24 | 24 | 24 | 22 |
Shares Change (YoY) | 2.12% | 1.23% | 0.93% | 9.58% | 0.88% |
EPS (Basic) | 0.03 | -4.83 | -1.23 | -3.11 | 4.86 |
EPS (Diluted) | 0.03 | -4.83 | -1.23 | -3.11 | 4.74 |
EPS Growth | - | - | - | - | 17.91% |
Free Cash Flow | 91.8 | 124.66 | 82.31 | -152.44 | 199 |
Free Cash Flow Per Share | 3.69 | 5.11 | 3.42 | -6.39 | 9.14 |
Gross Margin | 36.84% | 34.63% | 32.75% | 30.60% | 37.34% |
Operating Margin | 4.90% | 4.09% | 2.12% | -0.16% | 10.74% |
Profit Margin | 0.03% | -4.94% | -1.31% | -3.26% | 7.83% |
Free Cash Flow Margin | 4.11% | 5.23% | 3.64% | -6.69% | 15.12% |
EBITDA | 310.08 | 316.92 | 276.61 | 231.58 | 231.11 |
EBITDA Margin | 13.90% | 13.30% | 12.24% | 10.16% | 17.56% |
D&A For EBITDA | 200.74 | 219.51 | 228.77 | 235.15 | 89.7 |
EBIT | 109.33 | 97.41 | 47.84 | -3.57 | 141.41 |
EBIT Margin | 4.90% | 4.09% | 2.12% | -0.16% | 10.74% |
Effective Tax Rate | 76.90% | - | - | - | 16.28% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.